EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Doxorubicin compromises blood-brain barrier integrity by suppressing annexin A1 expression

Nan Hu, Weiran Liu, Sicong Jiang, Yiqing Yin

Open Life Sciences · 23.01.2026 · 21 (1)

DOI: 10.1515/biol-2025-1297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Life Sciences, online erschienen am 11.05.2026. Verfasst von Nan Hu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory o…. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Annexin A1 (ANXA1) is essential for blood-brain barrier (BBB) integrity, and its expression may be negatively regulated by the AP-1/miR-196a axis, while doxorubicin (DOX) is known to disrupt the BBB – though the underlying mechanism linking these factors remains unclear. To investigate how DOX impairs BBB integrity, we performed in vitro experiments on bEnd.3 brain microvascular endothelial cells and in vivo experiments on juvenile CD1 mice. In vitro , cells were treated with 1 μM DOX for 48 h, with or without pretreatment with 50 μM AP-1 inhibitor (SR11302) or 50 nM miR-196a inhibitor (LNA-antimiR-196a) for 24 h; in vivo , mice received weekly intraperitoneal injections of 4 mg/kg DOX for 5 weeks, with or without 1 h pretreatment with 10 mg/kg AP-1 inhibitor (SP600125) or 5 mg/kg LNA-antimiR-196a. Western blot was used to detect the expression of BBB tight junction proteins (occludin, claudin-5, ZO-1) and pathway molecules (AP-1, miR-196a, ANXA1), and Evans blue extravasation assay was employed to evaluate BBB permeability. Results showed that DOX increased BBB permeability by downregulating tight junction proteins, an effect associated with reduced ANXA1 expression. Further analyses revealed that miR-196a directly targets ANXA1 to suppress its expression, and AP-1 promotes miR-196a upregulation, thereby mediating DOX-induced ANXA1 downregulation and subsequent BBB damage. Inhibition of AP-1 or miR-196a reversed these DOX-induced abnormalities. Collectively, our findings demonstrate that DOX compromises BBB integrity by activating the AP-1/miR-196a axis, which suppresses ANXA1 and ultimately disrupts tight junctions – providing a novel mechanistic basis for DOX-induced neurotoxicity.

Schlagwörter

Stichwörter der Autor:innen

AP-1annexin A1blood-brain barrierchemotherapymiR-196a

Autor:innen und Institutionen

  • Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.
  • Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Geneva, Switzerland.

Zitieren

APA

Hu, N., Liu, W., Jiang, S., & Yin, Y. (2026). Doxorubicin compromises blood-brain barrier integrity by suppressing annexin A1 expression. Open Life Sciences, 21(1). https://doi.org/10.1515/biol-2025-1297

Vancouver

Hu N, Liu W, Jiang S, Yin Y. Doxorubicin compromises blood-brain barrier integrity by suppressing annexin A1 expression. Open Life Sciences. 2026;21(1). doi:10.1515/biol-2025-1297

BibTeX
@article{Hu2026,
  author = {Hu, Nan and Liu, Weiran and Jiang, Sicong and Yin, Yiqing},
  title = {Doxorubicin compromises blood-brain barrier integrity by suppressing annexin A1 expression},
  journal = {Open Life Sciences},
  year = {2026},
  volume = {21},
  number = {1},
  doi = {10.1515/biol-2025-1297}
}
Kostenlos starten →